Robert Harrington to Infusions, Intravenous
This is a "connection" page, showing publications Robert Harrington has written about Infusions, Intravenous.
Connection Strength
0.740
-
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. Am Heart J. 2016 Oct; 180:22-8.
Score: 0.128
-
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. Eur Heart J Acute Cardiovasc Care. 2013 Sep; 2(3):246-55.
Score: 0.105
-
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009 Dec 10; 361(24):2318-29.
Score: 0.081
-
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation. 2002 May 21; 105(20):2385-91.
Score: 0.048
-
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10?854 patients from the CHAMPION PHOENIX trial. Eur Heart J. 2018 12 07; 39(46):4112-4121.
Score: 0.038
-
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. N Engl J Med. 2017 05 25; 376(21):2032-2042.
Score: 0.034
-
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. Am Heart J. 2017 Jun; 188:147-155.
Score: 0.034
-
Cangrelor With and Without Glycoprotein?IIb/IIIa Inhibitors in?Patients?Undergoing Percutaneous?Coronary Intervention. J Am Coll Cardiol. 2017 Jan 17; 69(2):176-185.
Score: 0.033
-
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation. 2016 Sep 06; 134(10):723-33.
Score: 0.032
-
Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. Int J Cardiol. 2016 Jan 15; 203:708-13.
Score: 0.031
-
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J. 2016 Apr 07; 37(14):1122-30.
Score: 0.030
-
Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014 Apr; 29(4):833-42.
Score: 0.026
-
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012 May; 163(5):768-776.e2.
Score: 0.024
-
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 Dec 10; 361(24):2330-41.
Score: 0.020
-
Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 May 21; 360(21):2176-90.
Score: 0.019
-
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J. 2007 May; 28(9):1109-16.
Score: 0.017
-
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):549S-575S.
Score: 0.014
-
Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol. 2003 Sep 15; 92(6):651-5.
Score: 0.013
-
An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thrombolysis. 2002 Aug; 14(1):33-42.
Score: 0.012